Systemic inflammation and imbalance between endothelial injury and repair, the latter referred to as vascular incompetence, are associated with atherosclerosis and cardiovascular risk. Psoriasis, an inflammatory disease of the skin, has been associated with atherosclerosis. We investigated whether, in psoriasis, inflammation and vascular incompetence are associated with carotid intima-media thickness (cIMT) irrespective of metabolic syndrome and other established cardiovascular risk factors.
Methods
High sensitivity C-reactive protein (hsCRP), the ratio between endothelial microparticles (EMPs) and progenitors (EPCs), a marker of vascular incompetence, and cIMT were measured in 84 patients with psoriasis and 90 healthy controls, balanced for age, gender and the prevalence of metabolic syndrome.
Results
Patients with psoriasis had higher hsCRP, EMP/EPC ratio and cIMT than controls. Patients with both psoriasis and metabolic syndrome had the highest hsCRP levels, psoriasis and metabolic syndrome being associated with a 3.1- and 2.6-fold increased risk of having high hsCRP levels, respectively. Logarithm transformed hsCRP and EMP/EPC ratio were predictors of high cIMT (odds ratio 3.8; 95% confidence interval 1.3–11.4; p = 0.02 and odds ratio 8.7; 95% confidence interval 2.7–27.5; p < 0.001, respectively) regardless of confounders. Patients with high hsCRP and EMP/EPC ratio had higher cIMT than those with none or at least one of risk variable.
Conclusions
Patients with psoriasis have an increased burden of cardiovascular risk, including inflammation, vascular incompetence and early atherosclerosis. Increased hsCRP levels, possibly sustained by the inflammatory nature of psoriasis and metabolic syndrome, and vascular incompetence are associated with early carotid atherosclerosis, regardless of metabolic syndrome and other established cardiovascular risk factors.
LibbyP. Inflammation in atherosclerosis. Nature2002; 420: 868–874.
2.
PirroMBergeronJDagenaisGR. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med2001; 161: 2474–2480.
3.
KaptogeSDi AngelantonioELoweG. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet2010; 375: 132–140.
4.
BalciDDBalciAKarazincirS. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol2009; 23: 1–6.
5.
El-MongySFathyHAbdelazizA. Subclinical atherosclerosis in patients with chronic psoriasis: A potential association. J Eur Acad Dermatol Venereol2010; 24: 661–666.
6.
TroitzschPPaulista MarkusMR. Psoriasis is associated with increased intima-media thickness – the Study of Health in Pomerania (SHIP). Atherosclerosis2012; 225: 486–490.
7.
AntonucciVATengattiniVBalestriR. Intima-media thickness in an Italian psoriatic population: Correlation with lipidic serum levels, PASI and BMI. J Eur Acad Dermatol Venereol2012; 31: 1–4.
8.
AltekinERKoçSKarakaşMS. Determination of subclinical atherosclerosis in plaque type psoriasis patients without traditional risk factors for atherosclerosis. Turk Kardiyol Dern Ars2012; 40: 574–580.
9.
YiuKHYeungCKZhaoCT. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med2013; 273: 273–282.
10.
PietrzakABartosińskaJChodorowskaG. Cardiovascular aspects of psoriasis: An updated review. Int J Dermatol2013; 52: 153–162.
11.
DowlatshahiEAKavousiMNijstenT. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: The Rotterdam Study. J Invest Dermatol2013; 133: 2347–2354.
12.
ReichK. The concept of psoriasis as a systemic inflammation: Implications for disease management. J Eur Acad Dermatol Venereol2012; 26: 3–11.
13.
ArmstrongAWHarskampCTArmstrongEJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol2013; 68: 654–662.
14.
SabatierFCamoin-JauLAnfossoF. Circulating endothelial cells, microparticles and progenitors: Key players towards the definition of vascular competence. J Cell Mol Med2009; 13: 454–471.
15.
Jourde-ChicheNDouLCeriniC. Vascular incompetence in dialysis patients – protein-bound uremic toxins and endothelial dysfunction. Semin Dial2011; 24: 327–337.
16.
MannarinoEPirroM. Endothelial injury and repair: A novel theory for atherosclerosis. Angiology2008; 59: 69S–72S.
17.
PirroMBocciEBDi FilippoF. Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: Improvement with corticosteroid treatment. J Intern Med2012; 272: 177–184.
18.
RautouPEVionACAmabileN. Microparticles, vascular function, and atherothrombosis. Circ Res2011; 109: 593–606.
19.
BoulangerCMScoazecAEbrahimianT. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation2001; 104: 2649–2652.
YongPJ1KohCHShimWS. Endothelial microparticles: Missing link in endothelial dysfunction?Eur J Prev Cardiol2013; 20: 496–512.
22.
HillJMZalosGHalcoxJP. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med2003; 348: 593–600.
23.
Schmidt-LuckeCRössigLFichtlschererS. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation2005; 111: 2981–2987.
24.
PelletierFGarnache-OttouFAngelotF. Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. J Invest Dermatol2011; 131: 1573–1576.
25.
Martínez-Sales V, Vila V, Ricart JM, et al. Increased circulating endothelial cells and microparticles in patients with psoriasis. Clin Hemorheol Microcirc. Epub ahead of print 3 September 2013. DOI: 10.3233/CH-131766.
26.
Batycka-BaranAPaprockaMKrawczenkoA. Reduced number of circulating endothelial progenitor cells (CD133+/KDR+) in patients with plaque psoriasis. Dermatology2012; 225: 88–92.
27.
AlbertiKGEckelRHGrundySM. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation2009; 120: 1640–1645.
28.
PearsonTAMensahGAAlexanderRW. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003; 107: 499–511.
29.
PerkJDe BackerGGohlkeH. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol2012; 19: 585–667.
30.
PirroMSchillaciGPaltricciaR. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol2006; 26: 2530–2535.
31.
DowlatshahiEAvan der VoortEAArendsLR. Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis. Br J Dermatol2013; 169: 266–282.
32.
CombesVSimonACGrauGE. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest1999; 104: 93–102.
33.
RooneyPConnollyMGaoW. Notch-1 mediates endothelial cell activation and invasion in psoriasis. Exp Dermatol2014; 23: 113–118.
AblinJNGoldsteinZAloushV. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol Int2009; 29: 257–262.
36.
Rodríguez-CarrioJde PazBLópezP. IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients. PLoS One2014; 9: e86069–e86069.
37.
RidkerPMWilsonPWGrundySM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?Circulation2004; 109: 2818–2825.
38.
CasasJPShahTHingoraniAD. C-reactive protein and coronary heart disease: A critical review. J Intern Med2008; 264: 295–314.
39.
JeppesenJHansenTWOlsenMH. C-reactive protein, insulin resistance and risk of cardiovascular disease: A population-based study. Eur J Cardiovasc Prev Rehabil2008; 15: 594–598.
40.
AnandSSYusufS. C-reactive protein is a bystander of cardiovascular disease. Eur Heart J2010; 31: 2092–2096.
41.
FengBChenYLuoY. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis2010; 208: 264–269.
42.
LeroyerASTedguiABoulangerCM. Role of microparticles in atherothrombosis. J Intern Med2008; 263: 528–537.
43.
Awan Z and Genest J. Inflammation modulation and cardiovascular disease prevention. Eur J Prev Cardiol. Epub ahead of print 7 April 2014. DOI: 10.1177/2047487314529350.
